![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1790351
¹Ì±¹ÀÇ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® ¸®Æ÷Æ® : Á¦Ç°¡¤¼ºñ½ºº°, À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, ºÎ¹® ¿¹Ãø(2025-2033³â)U.S. Microarray Market Size, Share & Trends Analysis Report By Product & Services (Instruments, Consumables, Software & Services), By Type (DNA Microarray, Protein Microarray), By Application, By End Use, And Segment Forecasts, 2025 - 2033 |
¹Ì±¹ÀÇ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 26¾ï 5,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2025-2033³â¿¡ CAGR 5.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
½ÃÀåÀ» ÁÖµµÇÏ´Â °ÍÀº ¸ÂÃãÇü ÀÇ·á, ƯÈ÷ Á¤¹Ð Á¾¾çÇÐ ¹× ¾à¹°À¯ÀüüÇп¡ ´ëÇÑ ¼ö¿äÀÇ ±ÞÁõÀÔ´Ï´Ù. NIH, ´ëÇÐ, »ý¸í°øÇÐ ±â¾÷ÀÇ ÅõÀÚ°¡ Áõ°¡Çϰí ÀÖ´Â °¡¿îµ¥, ¸¶ÀÌÅ©·Î¾î·¹ÀÌ´Â ¹ÙÀÌ¿À¸¶Ä¿ ½Äº°, À¯ÀüÀÚ ¹ßÇö ÇÁ·ÎÆÄÀϸµ, Ä¡·á ¿ä¹ý Á¶Á¤, ³ª¾Æ°¡ ȯÀÚ ¿¹ÈÄ °³¼±¿¡ ¸Å¿ì À¯¿ëÇÕ´Ï´Ù. ¶ÇÇÑ ¾Ï°ú ¸¸¼ºÁúȯÀÇ È®»êÀÌ ½É°¢ÇØÁü¿¡ µû¶ó Á¶±â ¹ß°ß°ú ½Å¾à°³¹ßÀ» À§ÇÑ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ¿Í °°Àº °í¼º´É À¯Àüü Åø¿¡ ´ëÇÑ ½Å·Ú°¡ ´õ¿í ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.
ÃÖ±Ù ¾Ï ¿¬±¸ÀÇ ¹ßÀüÀº Áø´Ü Á¤È®µµ¿Í ºÐÀÚ ÇÁ·ÎÆÄÀϸµÀ» Çâ»ó½Ã۱â À§ÇØ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ Àåºñ¿Í ½Ã¾àÀ» Å©°Ô Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. ¸¶ÀÌÅ©·Î¾î·¹ÀÌ Ç÷§ÆûÀº À¯ÀüÀÚ ¹ßÇö ÇÁ·ÎÆÄÀϸµ¿¡ Á¡Á¡ ´õ ¸¹ÀÌ »ç¿ëµÇ°í ÀÖÀ¸¸ç, ¿¬±¸ÀÚµéÀº ¾Ï ƯÀ¯ÀÇ ¹ÙÀÌ¿À¸¶Ä¿¸¦ ½Äº°Çϰí, ¿¹Èĸ¦ ¿¹ÃøÇϰí, Ç¥Àû Ä¡·á¹ýÀ» ¾È³»ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¹Ì±¹¿¡¼´Â Thermo Fisher Scientific, Agilent Technologies, Illumina µîÀÇ ±â¾÷ÀÌ Á¾¾ç »ý°Ë ºÐ¼®¿¡ ÇʼöÀûÀÎ °í󸮷® ºÐ¼®°ú ÀúÅõÀÔ RNA/DNA »ùÇÿ¡ ÃÖÀûÈµÈ ÃֽŠ½Ã¾à ŰƮ¸¦ Ãâ½ÃÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î Thermo FisherÀÇ GeneChip Á¶»ç ½Ã¾àÀº ¾Ï ¿¬±¸¿¡¼ Àüü Àü»çü ºÐ¼®À» Áö¿øÇϰí, AgilentÀÇ SureTag DNA Ç¥Áö ŰƮ´Â ¾Ï ¼¼Æ÷ À¯ÀüÇп¡¼ ºñ±³ À¯Àüü ÇÏÀ̺긮µ¥À̼Ç(CGH)À» À§ÇÑ °ß°íÇÑ ÇÏÀ̺긮µ¥À̼ÇÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. iScan ½Ã½ºÅÛ°ú ±¤¹üÀ§ÇÏ°Ô È£È¯µÇ´Â IlluminaÀÇ Infinium ºÐ¼® ŰƮ´Â ¸ÞÆ¿È ¹× SNP ÇÁ·ÎÆÄÀÏÀ» µ¿½Ã¿¡ ºÐ¼®ÇÒ ¼ö ÀÖÀ¸¸ç, ÈļºÀ¯ÀüÇÐÀû ¾Ï ¿¬±¸¸¦ Áö¿øÇÕ´Ï´Ù.
¹Ì±¹À» Áß½ÉÀ¸·Î ÇÑ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ±â¼ú¿¡ ´ëÇÑ ÅõÀÚ¿Í Çõ½ÅÀÇ È®´ë´Â ƯÈ÷ Çdz» ÆÐÄ¡ Àü´Þ°ú °°Àº Â÷¼¼´ë ¿ëµµ¿¡¼ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÈÇÒ ¼ö ÀÖ´Â ¿©°ÇÀ» Á¶¼ºÇϰí ÀÖ½À´Ï´Ù. 2023³â 3¿ù, ¸Å»çÃß¼¼Ã÷¿¡ º»»ç¸¦ µÐ »ý¸í°øÇÐ ±â¾÷ Vaxx Technologies´Â MIMIX ¼¹æÇü Çdz» ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ÆÐÄ¡ Ç÷§ÆûÀ» ÃßÁøÇϱâ À§ÇØ 900¸¸ ´Þ·¯ÀÇ Ãß°¡ ÀÚ±ÝÀ» È®º¸Çß½À´Ï´Ù. ÀÌ »õ·Î¿î Ç÷§ÆûÀº ÇǺΠÆÐÄ¡¸¦ ÅëÇÑ ÀÚ°¡ Åõ¿©, ¼¹æÇü Åõ¿©¸¦ °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á ¹é½Å°ú Ä¡·áÁ¦ÀÇ Àü´Þ¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°íÀÚ ÇÕ´Ï´Ù. RA ijÇÇÅ» ¸Å´ÏÁö¸ÕÆ®, ¿£Áø(¸Å»çÃß¼¼Ã÷°ø´ë º¥Ã³ÆÝµå) µî ¹Ì±¹ À¯¸í ÅõÀÚÀÚµéÀÌ ÁÖµµÇÏ´Â À̹ø ÆÝµùÀº µ¶°¨ ¹é½Å°ú COVID-19 ¹é½ÅÀÇ ÁøÇà ÁßÀÎ ÀÓ»ó½ÃÇèÀ» Áö¿øÇϰí, Á¾¾çÇÐ, ÀÚ°¡¸é¿ªÁúȯ, ´ë»ç¼º Áúȯ¿¡ ´ëÇÑ Ç÷§ÆûÀÇ Àû¿ëÀ» È®´ëÇϱâ À§ÇÑ °ÍÀÔ´Ï´Ù. Ç÷§ÆûÀÇ Àû¿ëÀ» È®´ëÇÒ ¿¹Á¤ÀÔ´Ï´Ù.
ÇコÄÉ¾î ¿Ü¿¡µµ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ±â¼úÀº ¹Ì±¹ÀÇ ³ó¾÷°ú ȯ°æ °úÇÐ ºÐ¾ß¿¡¼ ÃßÁø·ÂÀ» ¾ò°í ÀÖ½À´Ï´Ù. Á¤¹Ð³ó¾÷¿¡¼ ¸¶ÀÌÅ©·Î¾î·¹ÀÌ´Â ½Ä¹° À¯ÀüüÀ» ÇØµ¶Çϰí ÇØÃæ ¹× ±âÈÄ ½ºÆ®·¹½º ¿äÀο¡ ´ëÇÑ ÀúÇ×¼ºÀ» ³ôÀÌ´Â ÇüÁúÀ» ½Äº°ÇÏ´Â µ¥ »ç¿ëµÇ¾î ¹Ì±¹ÀÇ ½Ä·®¾Èº¸ ¹®Á¦¸¦ ÇØ°áÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ È¯°æ±â°ü ¹× Çмú±â°ü¿¡¼´Â ¿À¿°¹°ÁúÀÌ Áö¿ª »ýŰèÀÇ À¯ÀüÀÚ ¹ßÇö¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡Çϱâ À§ÇØ ¸¶ÀÌÅ©·Î¾î·¹À̸¦ ÀÌ¿ëÇÑ µ¶¼ºÀ¯ÀüüÇÐ ºÐ¼®¹ýÀ» Ȱ¿ëÇÏ´Â »ç·Ê°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÓ»ó ¿¬±¸ºÎÅÍ Áö¼Ó°¡´É¼º±îÁö ´Ù¹æ¸éÀ¸·Î ÀÀ¿ëÇÒ ¼ö ÀÖ´Â ¸¶ÀÌÅ©·Î¾î·¹ÀÌ Àåºñ¿Í ½Ã¾àÀº ¹Ì±¹ °¢ ºÎ¹®ÀÇ Çõ½ÅÀ» ÃËÁøÇÏ´Â µ¥ ÀÖÀ¸¸ç, ±× ¿ªÇÒÀÌ °è¼Ó È®´ëµÇ°í ÀÖ½À´Ï´Ù.
The U.S. microarray market size was estimated at USD 2.65 billion in 2024 and is projected to grow at a CAGR of 5.7% from 2025 to 2033. The market is driven by the surging demand for personalized medicine, especially in precision oncology and pharmacogenomics. With rising investments from the NIH, universities, and biotech firms, microarrays are invaluable for identifying biomarkers, profiling gene expression, and tailoring therapeutic regimens-ultimately improving patient outcomes. In addition, the escalating prevalence of cancer and chronic diseases further enhances reliance on high-throughput genomic tools like microarrays for early detection and drug discovery.
Recent advancements in cancer research have significantly leveraged microarray instruments and reagents to enhance diagnostic accuracy and molecular profiling. Microarray platforms are increasingly used for gene expression profiling, allowing researchers to identify cancer-specific biomarkers, predict prognosis, and guide targeted therapies. In the U.S., companies such as Thermo Fisher Scientific, Agilent Technologies, and Illumina have introduced updated reagent kits optimized for high-throughput assays and low input RNA/DNA samples-critical for analyzing tumor biopsies. For instance, Thermo Fisher's GeneChip reagents support whole-transcriptome analysis in oncology research, while Agilent's SureTag DNA labeling kits enable robust hybridization for comparative genomic hybridization (CGH) in cancer cytogenetics. Illumina's Infinium assay kits, widely compatible with the iScan system, allow for simultaneous interrogation of methylation and SNP profiles, aiding in epigenetic cancer studies.
Growing investment and innovation in U.S.-based microarray technologies are poised to accelerate market growth, particularly in next-generation applications such as intradermal patch delivery. In March 2023, Vaxess Technologies, a Massachusetts-based biotech firm, secured an additional USD 9 million in funding to advance its MIMIX sustained-release intradermal microarray patch platform. This novel platform aims to revolutionize vaccine and therapeutic delivery by enabling self-administered, extended-release dosing through a skin patch. The funding, led by prominent U.S. investors such as RA Capital Management and The Engine (MIT's venture fund), will support ongoing clinical trials for influenza and COVID-19 vaccines and broaden the platform's applications into oncology, autoimmune diseases, and metabolic disorders.
Beyond healthcare, microarray technologies are gaining momentum in U.S. agriculture and environmental science. In precision farming, microarrays are used to decode plant genomes and identify traits that enhance resistance to pests and climate stressors, which are addressing U.S. food security challenges. Additionally, environmental agencies and academic institutions are increasingly using microarray-based toxicogenomic assays to evaluate the impact of pollutants on gene expression in local ecosystems. This multifaceted applicability-from clinical research to sustainability continues to expand the role of microarray instruments and reagents in driving innovation across sectors in the United States.
U.S. Microarray Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. microarray market report based on products and services, type, application, and end use.